Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime De Vrieze

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Personalized Medicine|August 29, 2024
Prostate Cancer Screening in Young MenMaxime De Vrieze, Rouvier Al-Monajjed, Matthias Boschheidgen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 13, 2026
Clinical validity of circulating tumor DNA as a diagnostic biomarker for prostate cancer: a systematic reviewMaxime De Vrieze, Nan Zhang, Petra Seibold, et al.
Clinical Genitourinary Cancer|May 18, 2019
Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder CancerMurat Akand, Tim Muilwijk, Yannic Raskin, et al.
Radiologie (Heidelberg, Germany)|June 17, 2024
Maxime De Vrieze, Anne Hübner, Rouvier Al-Monajjed, et al.
Radiologie (Heidelberg, Germany)|May 14, 2024
[Prostate cancer screening-current overview]Maxime De Vrieze, Anne Hübner, Rouvier Al-Monajjed, et al.
European Urology Oncology|July 10, 2025
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening TrialPeter Albers, Agne Krilaviciute, Petra Seibold, et al.
European Urology|May 15, 2024
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE TrialAgne Krilaviciute, Rudolf Kaaks, Petra Seibold, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Personalized Medicine|August 29, 2024
Prostate Cancer Screening in Young MenMaxime De Vrieze, Rouvier Al-Monajjed, Matthias Boschheidgen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 13, 2026
Clinical validity of circulating tumor DNA as a diagnostic biomarker for prostate cancer: a systematic reviewMaxime De Vrieze, Nan Zhang, Petra Seibold, et al.
Clinical Genitourinary Cancer|May 18, 2019
Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder CancerMurat Akand, Tim Muilwijk, Yannic Raskin, et al.
Radiologie (Heidelberg, Germany)|June 17, 2024
Maxime De Vrieze, Anne Hübner, Rouvier Al-Monajjed, et al.
Radiologie (Heidelberg, Germany)|May 14, 2024
[Prostate cancer screening-current overview]Maxime De Vrieze, Anne Hübner, Rouvier Al-Monajjed, et al.
European Urology Oncology|July 10, 2025
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening TrialPeter Albers, Agne Krilaviciute, Petra Seibold, et al.
European Urology|May 15, 2024
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE TrialAgne Krilaviciute, Rudolf Kaaks, Petra Seibold, et al.
Pageof 1